Need a Health professional?

Shreyaansh Lifesciences, Jaipur. India

Ado-trastuzumab Emtansine Injection 160 mg
Trastuzumab emtansine is used to treat certain types of breast cancer. This medication is used to treat tumors that produce more than the normal amount of a certain substance called HER2 protein. This medication is called a monoclonal antibody and microtubule inhibitor conjugate.

Ado-trastuzumab Emtansine Injection was approved for medical use in the United States in 2019. It is on the World Health Organization’s List of Essential Medicines.

Ado-trastuzumab Emtansine Injection Available Price In India UK Saudi Arabia

Ado-trastuzumab Emtansine Injection

  • Generic Brand Available – Kadcyla
  • API – Ado-trastuzumab Emtansine
  • Packaging – Glass Bottle
  • Strength – 160 mg

What is Ado-trastuzumab Emtansine Injection used for?

Ado-trastuzumab Emtansine Injection, Kadcyla (ado-trastuzumab emtansine) is a new class of chemotherapy drug called an antibody-drug conjugate used to treat breast cancer.

 

Disclaimer

All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

Get Access To Ado-trastuzumab Emtansine Injection 160 mg

Shreyaansh Lifesciences, Jaipur. India

Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act. 
Branch Offices in India : Jaipur | New Delhi

SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.

+91 99292 77766

Facts of Medicines

Ado-trastuzumab Emtansine Injection 160 mg

STORAGE AND HANDLING

Ado-trastuzumab Emtansine Injectionmust be refrigerated at 2°C to 8°C (36°F to 46°F). Do not use the Ado-trastuzumab Emtansine Injectioninjection beyond the expiration date located on the carton and the vial..

DOSAGE

The recommended dose of KADCYLA is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. Do not administer KADCYLA at doses greater than 3.6 mg/kg. Do not substitute KADCYLA for or with trastuzumab.

For intravenous infusion only. Do not administer as an intravenous push or bolus. Do not use Dextrose (5%) solution.

Management of adverse events (infusion-related reactions, hepatotoxicity, left ventricular cardiac dysfunction, thrombocytopenia, pulmonary toxicity or peripheral neuropathy) may require temporary

SIDE EFFECTS

The most common adverse drug reactions (frequency > 25%) with KADCYLA (n=884 treated patients) were fatigue, nausea, musculoskeletal pain, thrombocytopenia, headache, increased transaminases, and constipation..

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions, Hypersensitivity Reactions: Monitor for signs and symptoms during and after infusion. If significant infusionrelated reactions or hypersensitivity reactions occur, slow or interrupt the infusion and administer appropriate medical therapies. Permanently discontinue KADCYLA for life threatening infusion-related reaction.

Thrombocytopenia: Monitor platelet counts prior to each KADCYLA dose. Institute dose modifications as appropriate.

Neurotoxicity: Monitor for signs or symptoms. Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy.

Pulmonary Toxicity: Permanently discontinue KADCYLA in patients diagnosed with interstitial lung disease or pneumonitis.

    FAQs – Medicine Questions

    Ado-trastuzumab Emtansine Injection 160 mg
    Is ado-trastuzumab emtansine chemo?
    Kadcyla (ado-trastuzumab emtansine) is a new class of chemotherapy drug called an antibody-drug conjugate used to treat breast cancer.
    What is ado-trastuzumab emtansine used for?
    Ado-trastuzumab emtansine injection is used to treat HER2-positive metastatic breast cancer (cancer that has spread) in patients who have previously received other medicines (eg, trastuzumab, taxane medicine) that did not work well or whose cancer has returned during or within 6 months of completing treatment.
    Do you lose your hair with Kadcyla?
    Kadcyla doesn’t cause hair loss in most people who take the drug. And hair loss wasn’t reported as a side effect in Kadcyla’s prescribing information. In a trial that compared Kadcyla with another cancer treatment, hair loss did occur. But it wasn’t a common side effect with either drug.
    Where can I buy Ado-trastuzumab Emtansine Injection?

    You can buy Ado-trastuzumab Emtansine Injection from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

    The buyer should check the existing law in their home country before importing the product.

    What is the procedure to buy Ado-trastuzumab Emtansine Injection?

    Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020   We will reply ASAP with the details of the Ado-trastuzumab Emtansine Injection price as well as procurement procedure.

    Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

    What is the success rate of Kadcyla?
    The study was designed to measure disease-free survival, which is how long the patient stayed alive and cancer-free. After 3 years, the rate of disease-free survival was 88% in the Kadcyla group compared with 77% in the Herceptin group.

    NEWS / UPDATES

    1. Genentech Inc, [Revised on Sep 2020] [Accessed on 8th Apr 2021], https://www.gene.com/download/pdf/kadcyla_prescribing.pdf
    2. Roche Products Limited, Electronic Medicines Compendium (EMC), [Revised on Jul 2021] [Accessed on 4th Dec 2021], https://www.medicines.org.uk/emc/files/pil.5252.pdf
    3. Gunter von Minckwitz et al., Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N Engl J Med 2019; 380:617-628 [Accessed on 8th Apr 2021],  https://www.nejm.org/doi/full/10.1056/NEJMoa1814017
    4. Barok et al., Trastuzumab emtansine: mechanisms of action and drug resistance, Breast Cancer Research 2014, 16:209, [Accessed on 8th Apr 2021], https://www.researchgate.net/publication/262780064_Trastuzumab_emtansine_Mechanisms_of_action_and_drug_resistance